

1 **Supplementary Information for**

2

3 **Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione**
4 **metabolism**

5

6 Di Yu^{1,2,3, #}, Yang Liu^{1, #}, Yiqiang Zhou¹, Victor Ruiz-Rodado¹, Mioara Larion¹, Guowang
7 Xu^{2, #}, Chunzhang Yang^{1, #}

8

9 #Equal Contribution

10 ¹Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, MD,
11 20892, USA

12 ²CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of
13 Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China

14 ³University of Chinese Academy of Sciences, Beijing, 100049, China

15

16 **Correspondence: Chunzhang Yang, Ph.D.** Investigator, Neuro-Oncology Branch
17 Center for Cancer Research, NCI, NIH. Building 37, Room 1142E Bethesda, MD 20892.
18 Phone: +1-240-760-7083. Email: yangc2@mail.nih.gov

19

20 **Guowang Xu, Ph.D.** Professor, CAS Key Laboratory of Separation Science for Analytical
21 Chemistry, DICP, CAS. Building 18, Room 314, Dalian 116023. Phone: 0086-411-
22 84379530. Email: xugw@dicp.ac.cn

23

24 This file includes:

25 Supplementary Methods

26 Figure S1 and S2

27 SI Figure Legends

28

1 **Supplementary Methods**

2 **Genetic silencing**

3 Small interference RNA oligos targeting SLC7A11 were synthesized by Integrated DNA
4 Technologies (Coralville, IA). Negative control RNA was purchased from Qiagen (Hilden,
5 Germany). Oligos were transfected into GSC827 and TS603 cell lines using
6 Lipofectamine RNAiMax transfection reagent (Invitrogen) according to the manufacturer's
7 protocol. The siRNA sequences are shown as follows. siSLC7A11-1. F: 5'-AUG ACU
8 GUG CUU CCA AGU -3'; siSLC7A11-1. R: 5'-GAU GCA UAC UUG GAA GCA -3';
9 siSLC7A11-2. F: 5'-CUG UAA UGA GCU UGA UCG -3'; siSLC7A11-2. R: 5'-GAA CUU
10 GCG AUC AAG CUC -3'; siSLC7A11-3. F: 5'-UUC UUU AUA GUU GUU CCC -3';
11 siSLC7A11-3. R: 5'-CUG AAU UGG GAA CAA CUA -3'.

12

13 **Western blotting**

14 Total protein was extracted using RIPA lysis buffer (Thermo Fisher) supplemented with
15 protease and phosphatase inhibitor cocktail (Thermo Fisher). Protein quantification was
16 performed with the BCA Protein Assay Kit (Thermo Fisher Scientific). Equal amounts of
17 protein were separated on NuPAGE 4-12% Bis-Tris mini gels (Life Technologies) and
18 transferred to the membrane using the Power Blotter System (Invitrogen). The membrane
19 was incubated with antibodies and visualized with an HRP/chemiluminescence kit
20 (Thermo Fisher Scientific) on the ChemiDoc Imaging System (Bio-Rad). The primary
21 antibodies used included GCLC (Abcam, ab4163, 1:1000), GCLM (Proteintech, 14241-
22 1-AP, 1:1000), SLC7A11 (Abcam, ab37185, 1:1000), PARP (CST, 9532S, 1:1000),
23 γ H2A.X(CST, 7631P, 1:1000) and β -Actin (CST, 4970S, 1:5000).

24

25 **RNA extraction and quantitative real-time PCR (RT-PCR)**

26 Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen) and reverse
27 transcribed to cDNA using Superscript IV VILO Master Mix (Thermo Fisher). Gene
28 expression was analyzed with the Human Oxidative stress Plus PCR Array (PAHS-065YA,
29 Qiagen) or with the SYBR Green Power Master Mix Kit (Applied Biosystems). Primers
30 used include NFE2L2 (QT00027384), HMOX1 (QT00092645), NQO1 (QT00050281),
31 SLC7A11 (QT00002674) and ACTB (QT00095431), purchased from QIAGEN.

1

2 **Chromatin Immunoprecipitation (ChIP) assay**

3 ChIP assay was performed using the ChIP-IT Express Enzymatic kit (Active Motif) as
4 previously described (1). Control IgG and antibody targeting Nrf2 (Active Motif) were used.
5 For PCR amplification, the following primers specific for the GCLC, GCLM and SLC7A11
6 promoters were used. GCLC promoter, Forward: 5'- CGC AGT TGT TGT GAT ACA GCC
7 -3', Reverse: 5'- GGA CTG AGA CTT TGC CCT AAG AA -3'. GCLM promoter, Forward:
8 5'- ATT CCA AAC TGA GGG AGC TGT TT -3', Reverse: 5'- ATG AGT AAC GGT TAC
9 GAA GCA CT -3'. SLC7A11 promoter, Forward: 5'- AGC TTC CCA CAA AGT CGA AG
10 -3', Reverse: 5'- ACA TTC CTG CTT GTC TTG GT -3'. NQO1 promoter, Forward: 5'- TTT
11 GCT GAG TCA CCA GTG C-3', Reverse: 5'- TTT GCT GAG TCA CCA GTG C -3'. The
12 input DNA of each sample was used as a control.

13

14 **Caspase 3/7 activity assay**

15 Caspase 3/7 activity was measured using the Caspase-Glo 3/7 Assay (Promega). 10,000
16 Cells were seeded in 96-well plate and treated with DMSO, 30 nM triptolide or triptolide
17 combined with 0.1 mg/mL catalase for 24 hr. Luminescence was generated by adding
18 caspase-3/7 substrate and measured by Epoch plate reader.

19

20 **Annexin V/PI apoptosis assay**

21 Cell apoptosis was analyzed with the Annexin-V/PI Kit (Thermo Fisher) according to the
22 manufacturer's protocol. Cells were treated with DMSO, 30 nM triptolide, or triptolide
23 combined with 0.1 mg/mL catalase for 96 hr. Cells were harvested and stained with FITC
24 labeled Annexin-V and P.I. (Invitrogen) for 20 min on ice. Cell samples were analyzed by
25 the FACSCanto II flow cytometer (B.D.).

26

27 **Glutathione assay**

28 Total glutathione and oxidized glutathione disulfide (GSSG) were measured with the
29 GSH/GSSG-Glo Assay Kit (Promega) following the manufacturer's instructions. Total
30 glutathione minus GSSG equals reduced glutathione (GSH). Ten thousand cells were
31 seeded to a 96-well plate and treated with DMSO, 30 nM triptolide or triptolide combined

1 with 0.1mg/mL catalase for 24 hr. Luminescence was measured with a microplate reader
2 and normalized to the protein quantification.

3

4 **ROS assay**

5 ROS levels were measured using the ROS-Glo H₂O₂ Assay kit (Promega) and CM-
6 H₂DCFDA (Life Technologies) according to the manufacturer's instructions. For ROS-Glo
7 H₂O₂ Assay, cells were incubated with an H₂O₂ substrate, which can generate a luciferin
8 precursor. After adding the luciferin detection reagent, luminescence was measured using
9 a microplate reader and normalized to the protein levels. For CM-H₂DCFDA, cells were
10 resuspended in PBS containing ten μM CM-H₂DCFDA at 37 °C for 15 min. Cells were
11 analyzed by a FACSCanto II flow cytometer (B.D.).

12

13 **DNA damage assay**

14 DNA damage level was evaluated using DNA fragmentation, 8-oxoguanine level, and
15 comet assay. For DNA fragmentation assay, 300-500 ng of genomic DNA was resolved
16 by electrophoresis on 4-20% TBE gel (Invitrogen). The gel was then stained with SYBR
17 Safe and visualized on the Bio-Rad ChemiDoc Imaging System. The level of 8-oxoG was
18 measured using the DNA/RNA Oxidative Damage ELISA Kit (Cayman) according to the
19 manufacturer's protocol. An alkaline Comet assay was performed as previously described
20 (2). In brief, cells were resuspended in agarose, spread on glass slides, and lysed in lysis
21 buffer overnight at 4°C. Electrophoresis was performed at a voltage of 1 V/cm for 20 min.
22 After electrophoresis, DNA was stained by SYBR Safe and visualized by fluorescence
23 microscopy. The tail moment was measured and quantified by the OpenComet plugin of
24 ImageJ software (3).

25

26 **Cell proliferation**

27 Cell proliferation was analyzed using the Click-iT EdU Alexa Fluor 488 Imaging Kit
28 (Invitrogen), following the manufacturer's instructions. Fifteen thousand cells were
29 seeded to μ-slide 8-well chambered coverslips and treated with DMSO or 30 nM triptolide
30 for 24 hr after plating. After washing with PBS, cells were incubated with 10 μM EdU for
31 2 hr, and DNA was stained by Hoechst 33342. The cells labeled 488 azide were defined

1 as EdU positive cells. Images were taken by Zeiss LSM710 confocal microscope, and ten
2 random fields were analyzed using ImageJ software.

3

4 **Lipid peroxidation assay**

5 Lipid peroxidation was detected using the Image-iT™ Lipid Peroxidation Kit (Invitrogen).
6 Fifteen thousand cells were seeded to μ -slide 8-well chambered coverslips and treated
7 by DMSO, 30 nM triptolide, or triptolide combined with 0.1 mg/mL catalase for 24 hr. Live
8 cells were stained with 10 μ M dye for 30 min, and DNA was stained by Hoechst 33342
9 for 5 min. Images were taken using a Zeiss LSM710 confocal microscope. Five random
10 fields were analyzed using ImageJ software.

11

12 **Limited dilution assay**

13 Cells were counted and plated at clonal density for a limited dilution assay (125, 62, ...,
14 2 cells/well in 96-well plates). Cells were treated with DMSO or 30 nM triptolide for three
15 weeks and analyzed under a microscope. Cell clusters larger than 100 μ m in diameter
16 were defined as positive cells. The negative rate for each sample was calculated.

17

18 **Sphere formation assay**

19 Five thousand cells were seeded in 6-well plates and cultured in single-cell suspension
20 for the sphere formation assay. Cells were treated with DMSO, 30 nM triptolide, or 60 nM
21 triptolide for two weeks to allow sphere formation. Phase-contrast images were taken.
22 Spheres were counted from 10 random fields.

23

24 **Cell viability assay**

25 8,000 to 10,000 cells per well were seeded in 96-well plate. Cell viability was evaluated
26 using Cell Counting Kit-8 (Dojindo) according to the manufacturer's instructions.
27 Absorbance was measured at 450 nm using an Epoch plate reader (BioTek).

28


29 **Immunohistochemistry and TUNEL assay**

30 Immunohistochemistry was performed in tumor sections. The sections were
31 deparaffinized and rehydrated, and antigen retrieval was conducted by boiling in citrate

1 buffer (pH 6.0) for 5 min. The sections were incubated with primary antibodies overnight
2 at 4 °C, followed by HRP labeled secondary antibody at room temperature for 30 min.
3 Bound antibodies were visualized using a DAB kit. The primary antibodies used include
4 Nrf2 (CST, 1:1000), SLC7A11(Abcam, 1:500), GCLC (Abcam, 1:500), Ki67 (Abcam,
5 1:1,000) and PCNA (Santa Cruz, 1:1,000). TUNEL assay was performed using the
6 DeadEnd Colorimetric TUNEL System (Promega) following the manufacturer's protocol.
7 The slides were detected using DAB and counterstained using hematoxylin.

8


1 **SI Figures**



2

3 **Fig. S1. (A)** RT-PCR measured the siRNA knockdown efficiency of SLC7A11 in TB096
 4 cells. *** $p < 0.001$. **(B)** GSH/GSSG-Glo assay measured the GSH/GSSG ratio in TB096
 5 after siRNA knockdown of SLC7A11. ** $p < 0.01$. **(C)** ROS-Glo H₂O₂ assay measured the
 6 ROS level in TB096 cells after depletion of SLC7A11. ** $p < 0.01$. **(D)** Cell apoptosis assay
 7 using Annexin V and PI staining in TB096 cells after depletion of SLC7A11. **(E)**
 8 Quantification of apoptotic cells in Fig. S1D. *** $p < 0.001$, ** $p < 0.01$.

1



2

3

4 **Fig. S2. (A)** RT-PCR measured SLC7A11 expression in GSC827 and TB096 after treated
 5 with triptolide (30 nM, 24 hr). **p<0.01. **(B)** Luciferase reporter assay measured the ARE-
 6 driven transcriptional activity in GSC827 and TB096 cells. ***p<0.001. **(C)** ROS-Glo H₂O₂
 7 assay measured the ROS level in TB096 cells after treated with triptolide. ***p<0.001. **(D)**
 8 Caspase 3/7-Glo assay measured the caspase 3/7 activity in GSC827 and TB096 after
 9 treated with triptolide. ***p<0.001. **(E)** Cell apoptosis assay using Annexin V and PI
 10 staining in GSC827 and TB096 after treated with triptolide. Cata, Catalase. **(F)**
 11 Quantification of apoptotic cells in Fig. S2F. ***p<0.001. **(G)** Dose response cell viability
 12 assay using CCK8 assay in GSC827 and TB096 cells after treated with different doses
 13 of triptolide.

14

1 **References:**

- 2 1. Liu Y, *et al.* (2020) Targeting NRF2-Governed Glutathione Synthesis for SDHB-
3 Mutated Pheochromocytoma and Paraganglioma. *Cancers (Basel)* 12(2):280.
- 4 2. Olive PL & Banáth JP (2006) The comet assay: a method to measure DNA damage
5 in individual cells. *Nat. Protoc.* 1(1):23-29.
- 6 3. Lu Y, Liu Y, & Yang C (2017) Evaluating In Vitro DNA Damage Using Comet Assay.
7 *Journal of visualized experiments : JoVE* (128):56450.

8